AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04234308
Drug: Polyglycolic Acid
RxNorm normalized name: polyglycolic acid
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
Trial: NCT04234308
Drug: Polytetrafluoroethylene
RxNorm normalized name: polytetrafluoroethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)
Trial: NCT04234308
Drug: Polyamide
RxNorm normalized name: Polyamide-8
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
Trial: NCT00113763
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
Trial: NCT02037425
Drug: onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
Trial: NCT01116063
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
Trial: NCT00221338
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
Trial: NCT01287806
Drug: ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
Trial: NCT03657797
Drug: NCX 470
RxNorm normalized name: NCX 701
DrugBank: NCX 701 (DB05409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX 470 Ophthalmic Solution
Trial: NCT03657797
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost 0.005% Ophthalmic Solution
Trial: NCT00293787
Drug: Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Trial: NCT00293787
Drug: Latanoprost 0.005% Ophthalmic Solution (XALATAN)
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
Trial: NCT00293787
Drug: Timolol Maleate Ophthalmic Solution 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
Trial: NCT01368497
Drug: Entecavir and peginterferon
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
Trial: NCT00652054
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
Trial: NCT02729298
Drug: TP-0903
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
Trial: NCT01290549
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive escalating intravenous dose of polatuzumab vedotin.
Trial: NCT01290549
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.
Trial: NCT01348256
Drug: Dendritic cells vaccine
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with autologous dendritic cells loaded with autologous tumor antigens
Trial: NCT02177461
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177461
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177461
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02762929
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCI, via injection.
Trial: NCT01308203
Drug: Extended release niacin/laropiprant
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
Trial: NCT00751699
Drug: Asacol
RxNorm normalized name: Asacol
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asacol tablets, 6 tablets per day at 7 am for 7 days
Trial: NCT00751699
Drug: Asacol
RxNorm normalized name: Asacol
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
Trial: NCT00751699
Drug: Lialda
RxNorm normalized name: Lialda
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
Trial: NCT01479075
Drug: intransal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4x 40mU intranasal insulin
Trial: NCT01383707
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 5-FU 400 mg per meter-squared (mg/m\^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m\^2, continuous infusion over 46 hours up to 12 cycles.
Trial: NCT01383707
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
Trial: NCT01383707
Drug: Levofolinic acid
RxNorm normalized name: Levofolinic acid
DrugBank: Levoleucovorin (DB11596)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive levofolinic acid 200 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
Trial: NCT01383707
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
Trial: NCT02871011
Drug: Water
RxNorm normalized name: Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered as a footbath
Trial: NCT00102219
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01511042
Drug: Para-aminohippuric Acid
RxNorm normalized name: Para-aminohippuric acid
DrugBank: Aminohippuric acid (DB00345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH.
Trial: NCT01511042
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
Trial: NCT00002881
Drug: flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002881
Drug: goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002881
Drug: leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002881
Drug: suramin
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03523741
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine is administered orally according to individual prescribed dosing regimens.
Trial: NCT03395288
Drug: D-Mannose
RxNorm normalized name: d-mannose
DrugBank: Mannose (DB12907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 2 g D-mannose daily
Trial: NCT00402077
Drug: pramlintide acetate
RxNorm normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, three times a day, 120mcg
Trial: NCT00402077
Drug: sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet, once a day, 10mg
Trial: NCT00402077
Drug: phentermine
RxNorm normalized name: Phentermine
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet, once a day, 37.5mg
Trial: NCT01276041
Drug: pertuzumab in combination with trastuzumab and paclitaxel
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
Trial: NCT02347059
Drug: L-dopa
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antiparkinsonian medication
Trial: NCT02736552
Drug: S-1 for 6 months
RxNorm normalized name: (S)-1-butyl-2',6'-pipecoloxylidide
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 months S-1 after D2 resection
Trial: NCT00308178
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
Trial: NCT00919295
Drug: mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
Trial: NCT00994812
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
Trial: NCT03936036
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin dispensing claim is used as the exposure
Trial: NCT01495000
Drug: denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60mg subcutaneous injection, single dose
Trial: NCT04092309
Drug: ACE inhibitor, Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Search for Protective effect after chemotherapy and bone marrow transplantation
Trial: NCT02260661
Drug: AZD8835 in combination with fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
Trial: NCT02260661
Drug: AZD8835 in combination with fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
Trial: NCT04293393
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Trial: NCT04293393
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Trial: NCT00003744
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02303912
Drug: Nuc-1031 and Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
Trial: NCT03198338
Drug: 0.25% Bupivacaine, 0.5mL/kg
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
Trial: NCT00485264
Drug: Raltegravir poloxamer film coated tablet
RxNorm normalized name: raltegravir Chewable Tablet
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Final Selected Dose: 400-mg tablet taken orally twice daily.
Trial: NCT00485264
Drug: Raltegravir chewable tablet
RxNorm normalized name: raltegravir Chewable Tablet
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
Trial: NCT00485264
Drug: Raltegravir oral granules for suspension (20 mg/mL)
RxNorm normalized name: raltegravir Granules for Oral Suspension
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
Trial: NCT00485264
Drug: Raltegravir poloxamer film coated tablet
RxNorm normalized name: raltegravir Chewable Tablet
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet.
Trial: NCT03937505
Drug: IS-001
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection of IS-001 investigational drug
Trial: NCT00531167
Drug: combination of lamivudine+adefovir vs entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
Trial: NCT00326391
Drug: methylphenidate hydrochloride extended-release tablets
RxNorm normalized name: Methylphenidate Hydrochloride Extended-Release Tablets
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03503604
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
Trial: NCT03503604
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
Trial: NCT03503604
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion, 175 mg/m2 every 3 weeks
Trial: NCT03503604
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion, AUC=6 every 3 weeks
Trial: NCT03503604
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
Trial: NCT03503604
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion, AUC=4 every 3 weeks
Trial: NCT03503604
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
Trial: NCT00684372
Drug: leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Screening: If BK viremia (BK PCR \>10 000 copies/ml in serum) i. Reduced immunosuppression~1. MMF / AZA withdrawal~2. CNI reduction~   1. Tacrolimus 5 ng/ml in serum~  2. Cyclosporin 100 ng/ml in serum~3. Prednisolone to maintenance level~If effective =\> continue~* Stable renal function (P-Krea)~* \>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis~* Negative PCR at \> 3 months after diagnosis~If failure =\> add leflunomide~* Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy~* \<50% reduction in PCR at 4 weeks after diagnosis~* Positive PCR at \>3 months after diagnosis~Leflunomide dosing:~ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)~1. Starting at 20 mgx1 PO daily~2. Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 \>40 ug/ml
Trial: NCT05125640
Drug: Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)
RxNorm normalized name: progesterone 200 MG
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally, with 240 mL of water at dosing in sitting position
Trial: NCT02904772
Drug: alipogene tiparvovec
RxNorm normalized name: alipogene tiparvovec
DrugBank: Alipogene tiparvovec (DB13521)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: A dose of 1x10(\*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
Trial: NCT02904772
Drug: Cyclosporins
RxNorm normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
Trial: NCT02904772
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
Trial: NCT03575208
Drug: Pegylated interferon alfa (pegIFN)
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a 180 mcg weekly for 24 weeks